Avoro Capital Advisors LLC 4
4 · Whitehawk Therapeutics, Inc. · Filed Jun 15, 2026
Research Summary
AI-generated summary of this filing
Whitehawk (WHWK) 10% Owner Behzad Aghazadeh Receives 38,040-Share Award
What Happened
Behzad Aghazadeh, reported as a 10% owner (via Avoro Capital Advisors/Avoro Ventures), was granted a derivative award covering 38,040 shares of Whitehawk Therapeutics (WHWK) on June 12, 2026. The reported acquisition price is $0.00, and the grant is reported as a derivative (an option-type award per the filing). This is an award/grant (not an open-market purchase or sale).
Key Details
- Transaction date: June 12, 2026; Form 4 filed June 15, 2026.
- Transaction type/code: A (Grant / award / other acquisition); derivative instrument covering 38,040 shares; price reported $0.00.
- Vesting: Per footnote, 100% of the shares subject to the option vest on the earlier of (i) one year after the June 12, 2026 grant date or (ii) the day before the next annual meeting, provided the Reporting Person remains a Service Provider under the 2021 Equity Incentive Plan.
- Shares owned after transaction: Not specified in this filing.
- Reporting parties: Filed by Avoro Capital Advisors LLC, Avoro Ventures LLC and Behzad Aghazadeh; Dr. Aghazadeh serves as portfolio manager/controlling person of the Avoro entities. Footnote disclaimers state the Reporting Persons disclaim beneficial ownership except to the extent of pecuniary interest.
- Filing timeliness: Form 4 was filed three days after the grant (June 15 vs. June 12); the filing does not indicate a late filing code.
Context
This was a derivative grant (option-like award) subject to service-based vesting rather than an immediate purchase or sale. Because the reporting parties include Avoro investment entities and Dr. Aghazadeh is a 10% owner and portfolio manager, this filing reflects institutional/insider-affiliated awarding rather than typical executive open-market buying or selling. The award vests on a short schedule (up to one year) if service conditions are met; the filing gives no cash value or post-transaction total ownership figure.
Insider Transaction Report
- Award
Stock Option (right to buy)
[F1][F2][F3]2026-06-12+38,040→ 38,040 totalExercise: $4.16Exp: 2036-06-12→ Common Stock (38,040 underlying)
Footnotes (3)
- [F1]Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through such applicable date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one (1) year anniversary of the Date of Grant or (ii) the day immediately prior to the next annual meeting of stockholders following the Date of Grant. "Date of Grant" shall mean June 12, 2026.
- [F2]This Form 4 is filed by Avoro Capital Advisors LLC, a Delaware limited liability company ("Avoro Capital Advisors"), Avoro Ventures LLC, a Delaware limited liability company ("Avoro Ventures") and Behzad Aghazadeh ("Dr. Aghazadeh", and together with Avoro Capital Advisors and Avoro Ventures, the "Reporting Persons"). Dr. Aghazadeh serves as the portfolio manager and controlling person of Avoro Capital Advisors and Avoro Ventures LLC.
- [F3]The filing of this statement shall not be deemed an admission that any Reporting Person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.